The MANTRA study: a new umbrella concept prospectively applied to assess implantable medical devices for heart valve procedures.
And tricuspid heart valve
Aortic valve
Medical devices
Mitral valve
Study design
Journal
Journal of cardiothoracic surgery
ISSN: 1749-8090
Titre abrégé: J Cardiothorac Surg
Pays: England
ID NLM: 101265113
Informations de publication
Date de publication:
07 Apr 2023
07 Apr 2023
Historique:
received:
19
01
2023
accepted:
04
04
2023
medline:
11
4
2023
entrez:
7
4
2023
pubmed:
8
4
2023
Statut:
epublish
Résumé
Clinical evidence is commonly obtained through individual trials that are time-, cost- and resource-consuming, and which often leave unanswered clinically relevant questions. Umbrella studies have been developed to address the need for more efficient and flexible trial structures, predominantly for cancer treatments. The umbrella concept foresees data collection within a unifying trial structure, to which one or more substudies may be added at any time to address product- or therapy-specific questions. To our knowledge, the umbrella concept has not yet been used in the medical device area, but it may offer similar advantages as in other settings, particularly in areas where multiple therapies are available within one large treatment area. The MANTRA study (NCT05002543) is a prospective, global, post-marketing clinical follow-up study. The aim is to collect safety and device performance data covering the Corcym cardiac surgery portfolio for the treatment of aortic, mitral, and tricuspid valve diseases. The study uses a master protocol that outlines the main common parameters, and the specific questions are addressed in three substudies. The primary endpoints are device success at 30 days. Secondary endpoints include safety- and device performance-related data at 30 days, 1 year, and then annually through to 10 years. All endpoints are defined according to the more recent guidelines for heart valve procedures. Additionally, procedure and hospitalization information are collected, including Enhanced Recovery after Surgery in sites using such protocols, and patient outcome measures such as New York Heart Association classification and quality-of-life questionnaires. The study started in June 2021. Enrollment in all three substudies is ongoing. The MANTRA study will provide contemporary information on the long-term outcomes of medical devices for the treatment of aortic, mitral, and tricuspid heart valve diseases in routine clinical practice. The umbrella approach adopted in the study has the potential of longitudinally assessing long-term efficacy of the devices and the flexibility to investigate new research questions as they arise.
Sections du résumé
BACKGROUND
BACKGROUND
Clinical evidence is commonly obtained through individual trials that are time-, cost- and resource-consuming, and which often leave unanswered clinically relevant questions. Umbrella studies have been developed to address the need for more efficient and flexible trial structures, predominantly for cancer treatments. The umbrella concept foresees data collection within a unifying trial structure, to which one or more substudies may be added at any time to address product- or therapy-specific questions. To our knowledge, the umbrella concept has not yet been used in the medical device area, but it may offer similar advantages as in other settings, particularly in areas where multiple therapies are available within one large treatment area.
METHODS
METHODS
The MANTRA study (NCT05002543) is a prospective, global, post-marketing clinical follow-up study. The aim is to collect safety and device performance data covering the Corcym cardiac surgery portfolio for the treatment of aortic, mitral, and tricuspid valve diseases. The study uses a master protocol that outlines the main common parameters, and the specific questions are addressed in three substudies. The primary endpoints are device success at 30 days. Secondary endpoints include safety- and device performance-related data at 30 days, 1 year, and then annually through to 10 years. All endpoints are defined according to the more recent guidelines for heart valve procedures. Additionally, procedure and hospitalization information are collected, including Enhanced Recovery after Surgery in sites using such protocols, and patient outcome measures such as New York Heart Association classification and quality-of-life questionnaires.
RESULTS
RESULTS
The study started in June 2021. Enrollment in all three substudies is ongoing.
CONCLUSIONS
CONCLUSIONS
The MANTRA study will provide contemporary information on the long-term outcomes of medical devices for the treatment of aortic, mitral, and tricuspid heart valve diseases in routine clinical practice. The umbrella approach adopted in the study has the potential of longitudinally assessing long-term efficacy of the devices and the flexibility to investigate new research questions as they arise.
Identifiants
pubmed: 37029428
doi: 10.1186/s13019-023-02270-w
pii: 10.1186/s13019-023-02270-w
pmc: PMC10082523
doi:
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
110Informations de copyright
© 2023. The Author(s).
Références
Am Heart J. 2000 Mar;139(3):378-87
pubmed: 10689248
Heart Fail Rev. 2006 Sep;11(3):219-29
pubmed: 17041762
Circ Cardiovasc Qual Outcomes. 2015 Sep;8(5):469-76
pubmed: 26307129
Trials. 2019 Sep 18;20(1):572
pubmed: 31533793
N Engl J Med. 2017 Jul 6;377(1):62-70
pubmed: 28679092
Ann Thorac Surg. 2014 Feb;97(2):492-7
pubmed: 24268749
JAMA Surg. 2019 Aug 1;154(8):755-766
pubmed: 31054241
J Extra Corpor Technol. 2020 Jun;52(2):90-95
pubmed: 32669734
Eur Heart J Cardiovasc Imaging. 2018 Feb 1;19(2):176-184
pubmed: 28170033
Eur Heart J. 2021 May 14;42(19):1825-1857
pubmed: 33871579
Gen Thorac Cardiovasc Surg. 2017 Nov;65(11):627-632
pubmed: 28791582
Eur Heart J Cardiovasc Imaging. 2016 Jun;17(6):589-90
pubmed: 27143783
J Am Coll Cardiol. 2015 Jul 21;66(3):308-321
pubmed: 26184623